Refine by
Hematopoietic Stem Cells Articles & Analysis: Older
52 news found
Groups listed by CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer treatment · ...
Groups listed by the CDC as being at elevated risk of developing invasive mold infections include those who: · Have had a transplant, especially hematopoietic stem cell transplants · Have cancer, especially hematologic cancers like leukemia and lymphoma · Are undergoing cancer treatment · ...
The HLA gene products can be expressed on different cell surfaces and play critical roles in antigen presentation and immune signaling. ...
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
With the introduction of induced pluripotent stem cells (iPSCs) to our DeltEx platform, we possess a comprehensive suite of technologies and capabilities to target cancer with gamma-delta T cells,” stated William Ho, CEO and co-founder of IN8bio. ...
(Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced positive early data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic gamma-delta T cell therapy, in patients with high-risk acute myeloid leukemia (AML) undergoing ...
RESKUE is the first-in-human clinical trial where patients with Krabbe disease are administered FBX-101, a systemic adeno-associated virus (AAV) gene replacement strategy, after full myeloablation and hematopoietic stem cell transplantation (HSCT) infusion. Krabbe is a rare, genetic, neurodegenerative leukodystrophy affecting the central nervous ...
“The Dunbar CAR T-Cell Program has a superb facility designed specifically to advance the development of promising T-cell therapies. ...
FBX-101, a systemic AAV therapy administered after hematopoietic stem cell transplantation, was well tolerated in the first patient and the initial clinical data support normal brain development during this period of rapid myelination, and normal gross motor function,” stated Dr. ...
This program is an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). ...
The patent broadens the Company’s intellectual property coverage of genetically engineered innate immune cells beyond gamma-delta T cells to include NK cells. Like gamma-delta T cells, NK cells respond directly to cellular stress and have shown promise in cellular therapy clinical trials. ...
“My career has always been directed toward advancing novel disruptive therapies. Gamma-delta T cells are the prototype of ‘unconventional’ T cells, having both innate and adaptive immune properties. ...
Moreover, AFM28 also depleted leukemic cells from patient bone marrow without destroying CD34-positive/CD123-negative cells, suggesting sparing of hematopoietic stem and progenitor cells. ...
Phase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization) Posoleucel detected up to 12 weeks after last infusion Topline, unblinded study results from all 61 patients expected to be released ...
ByKalaris
This suggests SER-109 has a side effect profile comparable to placebo and may significantly reduce rCDI rates, which disproportionately affect cancer patients. Phase 1b Study of SER-155 in Stem Cell Transplant Hematopoietic stem cell transplant (HSCT) is frequently used to treat lymphoma, leukemia and multiple ...
(Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and ...
At one year, the overall survival without allogeneic hematopoietic stem cell transplantation across the cohort is 100% based on the Kaplan-Meier estimate. ...
NOT GATE: Endomucin (EMCN) NOT Logic Gated inhibitory CAR (iCAR) is engineered to protect healthy hematopoietic stem cells which are EMCN positive (EMCN+) from off-tumor toxicity, potentially increasing therapeutic specificity and improving post-treatment regeneration of a healthy hematopoietic system. ...
The results, which will be presented today during the “Disease models and Clinical Applications: Musculo-skeletal Diseases” poster session at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Washington, D.C., demonstrate that a gene therapy using hematopoietic stem cells (HSC) significantly ...
(Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell transplantation (HSCT) to avoid infection or ...